AB0737  AMINAPHTONE INCREASES SKIN BLOOD PERFUSION AND IMPROVES CLINICAL SYMPTOMS IN PATIENTS WITH RAYNAUD’S PHENOMENON INDEPENDENTLY FROM DIFFERENT TREATMENT BACKGROUNDS

B. Ruaro, C. Pizzorni, E. Gotelli, J. Aleshanid, A. Sulli. Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy

Background: Aminaphtone is a vasoactive drug that was recently demonstrated to improve both peripheral blood perfusion (BP) and clinical symptoms of Raynaud’s phenomenon (RP) in patients with either primary or secondary RP to systemic sclerosis (SSc).1-2

Objectives: The aim of this study was to evaluate possible interferences of different treatment backgrounds on both skin BP and RP-related clinical symptoms in patients treated with aminaphtone, during a six-month follow-up.

Methods: Forty-six patients with active RP were enrolled during routine clinical assessment after informed consent (11 primary RP, mean age 49±19 SD years, mean RP duration 6±3 years; and 35 secondary RP to systemic sclerosis, mean age 61±17 years, mean RP duration 11±9 years). Aminaphtone was orally administered 75 mg twice daily in addition to current treatments, and all patients were on a stable drug regimen for at least two months, which remained unmodified during the follow-up. All patients were taking cardioaspirin. Six groups of treatment backgrounds were identified: 1) no further treatments (12 patients); 2) hydroxychloroquine (2 patients); 3) colchicine (5 patients); 4) methotrexate (3 patients); 5) cyclosporine A (6 patients); 6) mycophenolate (6 patients); 7) proton-pump inhibitors (12 patients). Blood perfusion was measured by Laser Speckle Contrast Analysis (LASCA)3 at the level of fingertip, periumgal areas, dorsum and palm of hands, and face at baseline (T0), after one (T1), four (T4), twelve (T12) and twenty-four (T24) weeks of treatment. Raynaud’s condition score (RCS) and both frequency and duration of Raynaud’s attacks were assessed at the same time. Statistical analysis was performed by non-parametric tests.

Results: During aminaphtone treatment, a progressive statistically significant increase of blood perfusion, as well as an improvement of RP clinical symptoms (decrease of RCS, frequency and duration of RP attacks/day), were observed in all above reported seven groups of RP patients with different treatments backgrounds from T0 to T12 in all skin areas (p<0.01). There were no statistically significant difference between the seven groups of patients concerning skin BP at different times (p>0.60). The results were similar in both primary and secondary (SSc) RP patients (p=0.40). Aminaphtone administration had to be stopped in 2 patients due to headache, and one patient was lost during follow-up.

Conclusions: This study demonstrates that the increase of skin blood perfusion and the improvement of RP clinical symptoms is not influenced by different treatment backgrounds in RP patients treated with aminaphtone. These preliminary results should be further confirmed by a randomised blind clinical trial.

REFERENCES:

Disclosure of Interest: None declared


AB0738  IMPROVEMENT OF DERMAL THICKNESS IN SYSTEMIC SCLEROSIS PATIENTS TREATED WITH ENDOTHELIN RECEPTOR ANTAGONIST: LONG TERM STUDY BY HIGH FREQUENCY ULTRASOUND

B. Ruaro1, A. Sulli1, C. Pizzorni1, M. Ghio1, V. Smith2, V. Tomatis1, M. Cutolo1.
1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy; 2Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, Ghent University, Ghent, Belgium

Background: Systemic sclerosis (SSc) is a connective tissue disorder characterised by skin involvement, which may be evaluated by both modified Rodnan skin score (mRSS) and skin high frequency ultrasound (US).3-4 Endothelin-1 (ET-1) seems implicated in the development of dermal fibrosis in SSc.5 Bosentan, a dual ET-1 receptor antagonist seems effective in reducing skin fibrosis in SSc patients.6-7

Objectives: The aim of this study was to evaluate by US the long-term effects of bosentan on dermal thickness (DT) in SSc patients, in combination with long-term cyclic intravenous iloprost versus iloprost monotherapy.

Methods: Thirty-eight SSc patients were enrolled during their standard treatment for digital ischemia. At baseline (T0), 19 patients already receiving cyclic intravenous infusion of iloprost (5 continuous days, average 80 mcg/day, every two
months), continued the treatment for further 4 years (T4) (ILO group). Other 19 patients, although they continued the same cyclic intravenous iloprost treatment as the previous group, also received bosentan 125 mg twice a day for 4 years (ILO+BOS group), due to digital ulcers. DT was yearly evaluated by both US (18 MHz probe, MyLab 25, ESAOTE, Italy) and mRSS at the level of the usual seven skin areas (zygoma, fingers, dorsum of hands, forearms, upper-arms, chest, abdomen, thighs, legs, and feet). Non-parametric tests were used for the statistical analysis.

Results: A statistically significant decrease of DT, measured by US, was observed in the ILO+BOS group from T0 (median DT 1.135 mm) to T4 (median DT 1.088 mm) (p<0.01). No statistically significant variation of mRSS was observed during the follow-up in this group of patients (median mRSS at T0 12/51 and at T4 11/51, p=0.70). Conversely, in ILO group, a statistically significant increase of DT was observed after four years, as measured by US (median DT at T0 1.070 and at T4 1.258, p<0.0001), as assessed by mRSS (median mRSS at T0 4.51 and at T4 8.51, p<0.0001). Transient increase of transaminases was managed by temporary bosentan discontinuation.

Conclusions: In this open study, the long-term treatment with ET-1 receptor antagonist in combination with iloprost seems to be associated with a decrease of DT in SSc patients, in contrast to the treatment with iloprost alone. DT evaluated by US over long term seems to be more susceptible to change than by mRSS.


AB0740 EVALUATION OF HAND DERMAL THICKNESS AND PERIPHERAL BLOOD PERFUSION IN SYSTEMIC SCLERODEROSIS

B. Ruaro1, A. Sulli1, T. Santiago2,4, J.A. Pereira da Silva2,3, C. Pizzorni1, Y. Tomatis1, M. Cutolo1. 1Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy; 2Rheumatology Department, Centro Hospitalar e Universitário de Coimbra; 3Faculty of Medicine, University of Coimbra, Coimbra, Portugal

Background: Systemic sclerosis (SSc) is characterised by progressive skin involvement. The modified Rodnan Skin Score (mRSS) is the gold standard to assess skin damage, but it has significant limitations. Recently, several studies demonstrated the utility of skin high frequency ultrasound (US) as an alternative.

Objectives: The aim of this study was to identify possible correlations between peripheral blood perfusion (BP) and ultrasound dermal thickness (US-DT) at level of hand and finger in SSc patients.

Methods: Sixty-seven patients, satisfying the 2013 ACR/EULAR SSc criteria (mean age 64±9 SD years, mean disease duration 6±4 SD years) were enrolled. BP was measured as perfusion units (PU) by laser speckle contrast analysis (LASC) at the level of dorsal region of hands, and at the level of fingers, phalanges, dorsum of hand and fingers bilaterally. DT was evaluated by both US (18 MHz) and mRSS (median mRSS at T0 12/51 and at T4 8.51, p<0.0001). Transient increase of transaminases was managed by temporary bosentan discontinuation.

Conclusions: This study demonstrates a negative correlation between BP, as evaluated by LASC and DT, as evaluated by both US and mRSS at each skin site. SSc patients showed a statistically significant lower BP at the finger sites than healthy subjects (p<0.0001). No statistically significant difference in BP values was observed between SSc and healthy subjects at the dorsum of hands.


AB0741 T-REG AND TH17 LEVELS IN PATIENTS WITH SYSTEMIC SCLERODERMA

D. Uşküdar Çansu1, H. Üsküdar Tekeli2, C. Korkmaz3. 1Internal Medicine, Rheumatology; 2Internal Medicine, Hematology, Eskişehir Osmangazi University, Eskişehir, Turkey

Background: Regulatory T-cells (T-reg) may play an inhibitory role in the development of autoimmune diseases (AID) by suppressing the immune response to autoreactive T-cells. Impaired or decreased Th-17 levels and/or increased Th17 cells may be responsible for the development of AID. However, studies about the association of T-reg and systemic scleroderma (SSc) are limited and conflicting.

Objectives: Our aim is to determine whether there is a relationship between T-reg and Th-17 levels and disease activation in patients with SSc.

FUNCTIONAL MICROVASCULAR DAMAGE AND DT WORSENING IN THE PRESENT COHORT OF SSc PATIENTS SHOWING A PERSISTENT ‘LATE’ NVC PATTERN.


AB0744 T-REG AND TH17 LEVELS IN PATIENTS WITH SYSTEMIC SCLERODERMA

D. Uşküdar Çansu1, H. Üsküdar Tekeli2, C. Korkmaz3. 1Internal Medicine, Rheumatology; 2Internal Medicine, Hematology, Eskişehir Osmangazi University, Eskişehir, Turkey

Background: Regulatory T-cells (T-reg) may play an inhibitory role in the development of autoimmune diseases (AID) by suppressing the immune response to autoreactive T-cells. Impaired or decreased Th-17 levels and/or increased Th17 cells may be responsible for the development of AID. However, studies about the association of T-reg and systemic scleroderma (SSc) are limited and conflicting.

Objectives: Our aim is to determine whether there is a relationship between T-reg and Th-17 levels and disease activation in patients with SSc.